CML Multiple Sclerosis - 2011 - Fingolimod for the treatment of relapsing multiple sclerosis.


Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood–brain barrier in vitro. - May, 2012
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label Phase 2a proof-of-concept study. - April, 2012
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. - March, 2012
Pathophysiology of multiple sclerosis and the place of teriflunomide. - February, 2012
Permanent tremor reduction during thalamic stimulation in multiple sclerosis. - January, 2012
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. - December, 2011
Demographic and clinical characteristics of malignant multiple sclerosis. - November, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. - October, 2011
Reorganization in cognitive networks with progression of multiple sclerosis: insights from fMRI. - September, 2011
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. - August, 2011
Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis. - July, 2011
MRI only conversion to multiple sclerosis following a clinically isolated syndrome. - June, 2011
Switching multiple sclerosis patients with breakthrough disease to second-line therapy. - May, 2011
Fingolimod for the treatment of relapsing multiple sclerosis. - April, 2011
Headache in multiple sclerosis. - March, 2011
Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. - February, 2011
Early diffuse demyelinating lesion in the cervical spinal cord predicts a worse prognosis in relapsing-remitting multiple sclerosis. - January, 2011
Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. - December, 2010
Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry - November, 2010
Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. - October, 2010
Preserved brain adaptive properties in patients with benign multiple sclerosis. - September, 2010
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis - August, 2010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. - July, 2010
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. - June, 2010
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. - May, 2010
Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. - April, 2010
Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. - March, 2010
In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. - February, 2010
Progressive multifocal leukoencephalopathy after natalizumab monotherapy. - January, 2010
Accumulation of cortical lesions in MS: relation with cognitive impairment. - December, 2009
Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. - November, 2009
Opportunistic infections and other risks with newer multiple sclerosis therapies. - October, 2009
Diffusely abnormal white matter in chronic multiple sclerosis. - September, 2009
The relation between inflammation and neurodegeneration in multiple sclerosis brains. - August, 2009
Mitochondrial changes within axons in multiple sclerosis. - July, 2009
IFN-beta 1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. - June, 2009
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. - May, 2009
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a Phase I/II study. - April, 2009
Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. - March, 2009
Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. - February, 2009
Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. - January, 2009

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 23, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Multiple Sclerosis

» Advanced search

Paper of the Month - April, 2011

Fingolimod for the treatment of relapsing multiple sclerosis.

The Multiple Sclerosis and Movement Disorders Center at Advance Neurology at Cornerstone Health Care, Winston-Salem, NC, USA.
Expert Rev Neurother 2011;11:165–83.

View Archive »

READER POLL

Post Page On

SUBMIT AN ARTICLE


0 rating

May 23, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

CML Multiple Sclerosis » Advanced search